Amylyx faces an uphill battle

FDA approval decisions on neurology projects are rarely without controversy these days, and the case of Amylyx’s AMX0035 looks like being no exception. Briefing documents released by the FDA yesterday painted a damning picture, throwing into doubt the company’s claims of functional and survival benefits with the amyotrophic lateral sclerosis project in phase 2.